drugset / Trial / NCT00814125

ATAC - Endometrial Sub-Protocol

NCT00814125

Phase 3 Completed 285 enrolled AstraZeneca
RandomizedParallel-groupDouble-blind

Summary

To compare the difference between the ARIMIDEX group and the tamoxifen group in the incidence of abnormal endometrial histological findings arising after treatment has commenced.

Timeline

Start
1997-06
Primary completion
Completion
2005-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Anastrozole Other / unclassified 1 mg Oral
Comparator Tamoxifen Small molecule 20 mg Oral

Indications